Is ELIXF or ABBV a better dividend investment in 2026?

ELIXF currently yields 5970.15% with a 5% 5-year dividend growth rate. ABBV yields 3.06% with 8.9% growth. The better choice depends on your goal: ELIXF offers higher current income.

What is the dividend yield difference between ELIXF and ABBV?

ELIXF has a forward dividend yield of 5970.15% ($2.00/share annually). ABBV yields 3.06% ($6.65/share annually). The yield gap is 5967.09 percentage points.

Home › Compare › ELIXF vs ABBV

ELIXF vs ABBV: Dividend Comparison 2026

ELIXF yields 5970.15% · ABBV yields 3.06%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ELIXF wins by $349757300762301.88M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ELIXF

● Live price

5970.15%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$349757300762302.00M

Annual income

$338,600,487,421,434,700,000.00

Full ELIXF calculator →

ABBV

AbbVie Inc.

● Live price

3.06%

Share price

$217.44

Annual div

$6.65

5Y div CAGR

40.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$102.3K

Annual income

$24,771.77

Full ABBV calculator →

Portfolio growth — ELIXF vs ABBV

📍 ELIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ELIXF	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ELIXF + ABBV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ELIXF pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELIXF

Annual income on $10K today (after 15% tax)

$507,462.69/yr

After 10yr DRIP, annual income (after tax)

$287,810,414,308,219,520,000.00/yr

ABBV

Annual income on $10K today (after 15% tax)

$259.96/yr

After 10yr DRIP, annual income (after tax)

$21,056.00/yr

At 15% tax rate, ELIXF beats the other by $287,810,414,308,219,500,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELIXF + ABBV for your $10,000?

ELIXF: 50%ABBV: 50%

100% ABBV50/50100% ELIXF

Portfolio after 10yr

$174878650381151.06M

Annual income

$169,300,243,710,717,360,000.00/yr

Blended yield

96.81%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ELIXF

No analyst data

Altman Z

-68.9

Piotroski

2/9

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+17.8% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELIXF buys

ABBV buys

No recent congressional trades found for ELIXF or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricELIXFABBV

Forward yield	5970.15% ✓	3.06%
Annual dividend / share	$2.00	$6.65 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.6% ✓
Portfolio after 10y	$349757300762302.00M ✓	$102.3K
Annual income after 10y	$338,600,487,421,434,700,000.00 ✓	$24,771.77
Total dividends collected	$349006491373237.88M ✓	$61.0K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ELIXF vs ABBV ($10,000, DRIP)

Year	ELIXF Portfolio	ELIXF Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$607,715	$597,014.93	$11,550	$430.00	+$596.2K → ELIXF
2	$34,558,188	$33,907,932.79	$13,472	$627.96	+$34.54M → ELIXF
3	$1,839,034,548	$1,802,057,287.52	$15,906	$926.08	+$1839.02M → ELIXF
4	$91,591,647,409	$89,623,880,441.98	$19,071	$1,382.55	+$91591.63M → ELIXF
5	$4,269,634,661,039	$4,171,631,598,311.20	$23,302	$2,095.81	+$4269634.64M → ELIXF
6	$186,311,225,789,697	$181,742,716,702,385.70	$29,150	$3,237.93	+$186311225.76M → ELIXF
7	$7,611,116,385,606,142	$7,411,763,374,011,165.00	$37,536	$5,121.41	+$7611116385.57M → ELIXF
8	$291,118,268,537,960,000	$282,974,374,005,361,470.00	$50,079	$8,338.38	+$291118268537.91M → ELIXF
9	$10,426,928,355,950,688,000	$10,115,431,808,615,070,000.00	$69,753	$14,065.80	+$10426928355950.62M → ELIXF
10	$349,757,300,762,302,000,000	$338,600,487,421,434,700,000.00	$102,337	$24,771.77	+$349757300762301.88M → ELIXF

ELIXF vs ABBV: Complete Analysis 2026

ELIXF — Stock

Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cannabis-related businesses, which are fully licensed for cultivation, production, and/or sale of medical and specialty cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada.

Full ELIXF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

📬

Get this ELIXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELIXF vs SCHD ELIXF vs JEPI ELIXF vs O ELIXF vs KO ELIXF vs MAIN ELIXF vs JNJ ELIXF vs MRK ELIXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.